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The development of cancer is driven not only by ge-
netic mutations but also by epigenetic alterations.
Here, we show that TET1-mediated production of
5-hydroxymethylcytosine (5hmC) is required for the
tumorigenicity of glioblastoma cells. Furthermore,
we demonstrate that chromatin target of PRMT1
(CHTOP) binds to 5hmC. We found that CHTOP is
associated with an arginine methyltransferase com-
plex, termed the methylosome, and that this pro-
motes the PRMT1-mediated methylation of arginine
3 of histone H4 (H4R3) in genes involved in glioblas-
tomagenesis, including EGFR, AKT3, CDK6, CCND2,
and BRAF. Moreover, we found that CHTOP and
PRMT1 are essential for the expression of these
genes and that CHTOP is required for the tumorige-
nicity of glioblastoma cells. These results suggest
that 5hmCplays a critical role in glioblastomagenesis
by recruiting the CHTOP-methylosome complex to
selective sites on the chromosome, where it methyl-
ates H4R3 and activates the transcription of cancer-
related genes.
INTRODUCTION
Covalent modifications of DNA and histones influence transcrip-
tional activity and the timing of DNA replication, thereby regu-48 Cell Reports 9, 48–60, October 9, 2014 ª2014 The Authorslating cell proliferation, survival, self-renewal, and tumorigenesis
(Goldberg et al., 2007; Sasaki and Matsui, 2008). Methylation
at the five position of cytosine is one of the most abundant
modifications of DNA and is required for the regulation of gene
expression, genome stability, and genomic imprinting (Baylin
and Jones, 2011). This modification is mediated by the DNA
methyltransferase family of proteins and occurs predominantly
in CpG dinucleotides (Bird, 2001; Jones, 2012). It has recently
been shown that 5mC is oxidized to 5-hydroxymethylcytosine
(5hmC) by the ten-eleven translocation (TET) family of Fe(II)
and 2-oxoglutarate-dependent DNA dioxygenases, TET1TET3
(He et al., 2011; Ito et al., 2011; Tahiliani et al., 2009). 5hmC is
found in diverse cell types and developmental stages, including
embryonic stem cells and Purkinje cells (Cimmino et al., 2011;
Dawlaty et al., 2013; Guo et al., 2011; Hahn et al., 2013; Koh
et al., 2011; Wu and Zhang, 2014). More recently, 5hmC has
been shown to be successively oxidized to 5-formylcytosine
(5fC) and 5-carboxylcytosine (5caC) by the TET family of en-
zymes (He et al., 2011; Ito et al., 2011; Shen et al., 2014; Wu
and Zhang, 2014). 5hmC, 5fC, and 5caC are assumed to be
intermediates in DNA demethylation, and 5fC and 5caC can be
converted to unmodified cytosine by thymine-DNA glycosylase
(TDG) and by the base excision repair pathway (Guo et al.,
2011; He et al., 2011).
It has recently been shown that 5hmC acts not only as an
intermediate of DNA demethylation but also as an epigenetic
mark that recruits DNA-binding proteins. For example, it has
been shown that theMbd3/NURD complex regulates expression
of 5hmC-marked genes in embryonic stem cells (ESCs) (Yildirim
et al., 2011). It has also been reported thatMeCP2 binds to 5hmC
that is enriched within active genes as well as accessible chro-
matin in the nervous system (Melle´n et al., 2012). More recently,
it has been shown that 5mC, 5hmC, 5fC, and 5caC recruit
distinct sets of proteins in a dynamic and cell-type-dependent
manner (Spruijt et al., 2013). This result suggests that 5hmC,
5fC, and 5caC may recruit transcription regulators in certain
cell types, as well as DNA repair proteins that may also be
involved in DNA demethylation.
5hmC and the TET family of enzymes function in a diverse set
of biological processes, including embryogenesis and differenti-
ation (Cimmino et al., 2011; Dawlaty et al., 2013; Guo et al., 2011;
Hahn et al., 2013; Koh et al., 2011; Wu and Zhang, 2014). 5hmC
and TET family enzymes also play critical roles in the develop-
ment of cancer (Cimmino et al., 2011). TET1 was first identified
as part of a fusion gene with mixed lineage leukemia in patients
with acute myeloid leukemia (AML) (Ono et al., 2002). Further-
more, it has been reported that TET2 is frequently inactivated
by mutations or deletions in various myeloid leukemias, resulting
in the downregulation of 5hmC levels (Delhommeau et al., 2009).
It is also known that isocitrate dehydrogenase 1 and 2 (IDH1 and
IDH2) are mutated in AML, glioma, sarcoma, and melanoma
(Dang et al., 2009; Parsons et al., 2008; Ward et al., 2010).
Whereas wild-type IDHs generate a-ketoglutarate, mutated
IDHs produce an oncometabolite, 2-hydroxyglutarate, which in-
hibits the TET family of enzymes and thereby interferes with the
conversion of 5mC to 5hmC (Figueroa et al., 2010; Xu et al.,
2011). More recently, it has been reported that transcriptional
downregulation rather than mutation of TET family enzymes or
IDH can result in the depletion of 5hmC in many cancers,
including melanoma, breast, lung, and prostate cancers (Hsu
et al., 2012; Lian et al., 2012).
In the present study, we examined the levels of 5hmC and
TET1 in glioblastoma, the most malignant type of brain tumor,
which has a median survival of approximately 1 year (Furnari
et al., 2007; Stupp et al., 2005). We found that, in contrast to
previous studies of other tumor types (Cimmino et al., 2011),
proneural glioblastoma contain high levels of 5hmC and TET1
and that TET1-mediated production of 5hmC is required for
glioblastomagenesis. Furthermore, we found that 5hmC recruits
chromatin target of PRMT1 (CHTOP) associated with the meth-
ylosome (Friesen et al., 2001), which methylates arginine 3 on
histone H4 (H4R3) and activates the transcription of cancer-
related genes.
RESULTS
Glioblastoma Cells Contain Elevated Levels of 5hmC
and TET1
Glioblastoma cells cultured in serum-free conditions form
spheres and retain stem-cell-like properties and tumorigenicity
(Lee et al., 2006). We have previously described the isolation
and culture of glioblastoma cells from seven patients, desig-
nated GB1GB5, GB11, and GB13 (Koyama-Nasu et al.,
2013). DNA array analysis revealed that GB2GB5, GB11, and
GB13 resembled proneural glioblastoma cells, whereas GB1
resembled the mesenchymal type (Lottaz et al., 2010; Fig-
ure S1A). Furthermore, we performed quantitative RT-PCR
(qRT-PCR) analyses to examine the expression levels of markergenes indicating subtypes of glioblastoma in patient samples
(GBM3–GBM7) as well as in glioblastoma cell lines (GB1–GB5,
GB8, and GB21). We found that glioblastoma patient samples
and cell lines were classified into four subtypes: proneural,
neural, classical, and mesenchymal (Figure S1B). In addition,
we found that the glioblastoma cell lines and patient samples
used in this study do not have mutations in either IDH1 (R132)
or IDH2 (R172; Figure S1C).
Previous studies have reported that 5hmC was strongly
depleted in tissue stem cell compartments and human cancers
(Haffner et al., 2011; Hsu et al., 2012; Kraus et al., 2012; Lian
et al., 2012; Mu¨ller et al., 2012; Orr et al., 2012). However, our
dot blot analysis showed that GB2GB5, GB11, and GB13 cells,
but not GB1 cells, contained elevated levels of 5hmC compared
to HeLa, U87MG, and human neural progenitor cell lines (hNPCs)
(Figure 1A). Furthermore, absolute mRNA quantification using
qRT-PCR analyses revealed that TET1 expression levels were
significantly higher than those of the other TET family members
(TET2 and TET3) in GB2GB5, GB11, and GB13 cells and in
hNPCs, but not in GB1 cells (Figure 1B). Moreover, using a stable
isotope-labeled 5hmC as an internal standard, we quantified
the genomic content of 5hmC in glioblastoma cells by liquid
chromatography-mass spectrometry (LC-MS). We found that
5hmC accounts for about one percent of all genomic cytosines
in glioblastoma cells (Figure 1C). We also performed dot blot
analysis of glioblastoma patient samples and found that the
levels of 5hmC and TET1 expression were upregulated in pro-
neural glioblastoma, but not in other subtypes (Figures 1D, 1E,
and S1D–S1F). Thus, upregulation of TET1 may be responsible
for the elevated levels of 5hmC in the proneural subtypes.
TET1-Mediated Production of 5hmC Is Required
for Glioblastomagenesis
We next examined whether the TET family of genes is involved in
the proliferation and tumorigenicity of glioblastoma cells. Infec-
tion of GB2 cells with a lentivirus expressing a small hairpin
RNA (shRNA) or small interfering RNA (siRNA) targeting TET1 re-
sulted in a significant decrease in their growth (Figures 2A and
S2A). Knockdown of TET1 also suppressed sphere formation
of GB3GB5 cells (Figure 2B). Furthermore, we found that
overexpression of wild-type, but not of catalytic mutant TET1,
restored the growth and sphere formation of GB2 cells in which
TET1 had been knocked down (Figures 2A, 2C, and S2B).
Consistent with these results, overexpression of wild-type
TET1, but not of mutant TET1, restored the decreased levels of
5hmCcaused by knockdown of TET1 (Figure S2C). These results
suggest that TET1 is important for the proliferation of glioblas-
toma cells. We next infected GB2 cells with lentivirus-expressing
shRNAs directed against TET1 and intracranially transplanted
these into immunodeficient mice. Mice receiving the shRNA-
expressing GB2 cells survived significantly longer than those
receiving GB2 cells infected with a control lentivirus (Figure 2D).
Histopathological analysis of tumor xenografts demonstrated
that knockdown of TET1 inhibited glioblastoma progression,
whereas control GB2 cells formed invasive glioblastoma
(Figure 2E). Moreover, we found that overexpression of TET1
restored the tumorigenicity of GB2 cells in which TET1 had
been knocked down (Figure 2D). These results suggest thatCell Reports 9, 48–60, October 9, 2014 ª2014 The Authors 49
Figure 1. 5hmC and TET1 Levels in Human Glioblastoma Cells
(A) Dot blot analysis of genomic 5hmC and 5mC in human glioblastoma cells and NPCs.
(B) Absolute expression levels of the TET family of genes were determined by qRT-PCR. Copy numbers were calculated according to the standard curves
generated by known quantities of plasmids containing the TET family of genes. Data show the means ± SD of three independent experiments.
(C) LC-MS quantification of 5hmC in genomic DNA isolated from glioblastoma cells and HeLa cells. N.D., not detected.
(D) Dot blot analysis of genomic 5hmC in primary glioblastoma samples and cultured cells.
(E) Absolute expression levels of the TET family of genes in primary glioblastoma samples as determined by qRT-PCR. Data show the means ± SD of three
independent experiments.
See also Figure S1.TET1 plays a critical role in the tumorigenicity of glioblastoma
cells.
TET1-Catalyzed Enrichment of 5hmC Is Critical
for the Expression of Cancer-Related Genes
To identify hydroxymethylated loci on a genomic scale, we
immunoprecipitated 5-hydroxymethylated DNA using a 5hmC-
specific antibody and analyzed the DNA by high-throughput
sequencing (hMeDIP-seq). We found that the number of 5hmC
peaks was greater in the genome of GB2 cells compared to
the hNPC genome (Figure 3A). 5hmC was relatively enriched
within the intragenic regions and promoters, as previously
observed in mouse embryonic stem cells (Figures 3B and 3C).
Gene ontology analysis revealed that genes encoding compo-
nents of cancer-related signaling pathways and neuronal func-
tions are overrepresented among the hydroxymethylated genes
(Table S1). Furthermore, we identified intragenic 5hmC peaks in
the EGFR, AKT3, CDK6, CCND2, and BRAF genes (Figure 3D).
hMeDIP-qPCR assays to detect 5hmC in these five genes
confirmed the results of hMeDIP-seq analyses (Figure 3E). By
contrast, we could not detect 5hmC enrichment in these genes
in hNPCs. To elucidate the significance of elevated 5hmC con-
tent in these genes in glioblastoma cells, we examined the effect
of TET1 knockdown on their expression. We found that knock-50 Cell Reports 9, 48–60, October 9, 2014 ª2014 The Authorsdown of TET1 resulted in decreased expression of these five
genes (Figure 3F). Furthermore, we found that overexpression
of wild-type, but not of mutated, TET1 restored the expression
of these genes in GB2 cells in which TET1 had been knocked
down. Thus, TET1-mediated enrichment of 5hmCmay be critical
for their expression. EGFR and AKT3 are core components of
the RTK/RAS/PI(3)K-signaling pathway, whereas CDK6 and
CCND2 are key regulators of the RB-signaling pathway. These
two signaling pathways, together with the p53-signaling
pathway, are known to be frequently altered in glioblastoma.
Our results therefore suggest that the TET1-catalyzed enrich-
ment of 5hmC in these genes may drive the tumorigenicity of
glioblastomas.
5hmC Interacts with CHTOP in Glioblastoma Cells
Based on the above findings, we hypothesize that 5hmC is not
just an intermediate in DNA demethylation but functions as a
cis-acting modulator of gene activity. Consistent with this
notion, it has recently been reported that enrichment of 5hmC
is not associated with DNA demethylation during neurogenesis
(Hahn et al., 2013). To test our hypothesis, we attempted to
identify proteins that interact with 5hmC. We prepared syn-
thetic double-stranded DNA oligonucleotides that contain
three modified CpG residues (Figure S3A). We incubated
Figure 2. TET1 Is Required for the Tumori-
genicity of Glioblastoma Cells
(A) Growth curves of GB2 cells infected with a
lentivirus expressing shRNA targeting TET1 and/or
a lentivirus expressing wild-type or mutant TET1.
Data show the means ± SD of three independent
experiments.KD, knockdown.OE, overexpression.
(B) The numbers of spheres of glioblastoma
cells transfected with siRNA targeting TET1. Data
show the means ± SD of three independent
experiments.
(C) The number of spheres of GB2 cells infected
with a lentivirus expressing shRNA targeting TET1
and/or a lentivirus expressing wild-type or mutant
TET1. Data show the means ± SD of three inde-
pendent experiments.
(D) Kaplan-Meier survival curves of mice trans-
planted with 1.0 3 104 GB2 cells infected with
a lentivirus expressing shRNA targeting TET1 or
a lentivirus expressing wild-type or mutant TET1.
(E) Histological examination of tumors developed
in the mice in (D). At day 100, tissue sections
were stained with hematoxylin and eosin (HE)
or anti-GFP antibody. The scale bars represent
2 mm (upper panels) and 50 mm (lower panels).
See also Figure S2.30-biotin-tagged oligonucleotides with nuclear extracts from
GB2 cells. The bound proteins were precipitated with streptavi-
din-Dynabeads and subjected to LC-MS (Figure S3B). Among
the coprecipitated proteins identified (Table S2), we focused
our attention on CHTOP, because it preferentially bound to
the 5hmC-containing oligonucleotide versus the unmodified
or 5mC-containing oligonucleotide (Figure 4A, upper panel).
CHTOP is a chromatin-associated protein that is involved in
transcriptional regulation. It contains a glycine- and arginine-
rich (GAR) region, which interacts with RNA or DNA directly
or in combination with other nucleotide-binding proteins (Rajya-
guru and Parker, 2012). We generated recombinant CHTOP us-
ing a baculovirus system (Figure S3C) and confirmed that
CHTOP preferentially bound to 5hmC in vitro (Figure 4A, lower
panel). Moreover, we performed electrophoretic mobility shift
assays and found that CHTOP preferentially binds to the
5hmC-containing oligonucleotide (Figure S3D, left panel). Addi-
tion of an anti-CHTOP antibody induced a supershift of the
band (Figure S3D, middle panel), suggesting that the band de-
tected may indeed represent a complex consisting of CHTOP
and the 5hmC-containing oligonucleotide. By contrast, MBD1
specifically interacted with the 5mC-containing oligonucleotide
(Figure S3D, right panel).Cell Reports 9, 48–6CHTOP was first identified as a target
of protein arginine methyltransferases,
especially PRMT1 and PRMT5 (van Dijk
et al., 2010; Zullo et al., 2009). PRMT1
catalyzes the generation of both
monomethylarginine and asymmetrical
dimethylarginine residues, whereas
PRMT5 generates monomethylarginine
and symmetrical dimethylarginine resi-dues (Bedford andClarke, 2009;Martin and Zhang, 2005). Immu-
noblotting analysis of CHTOP with antibody against asymmet-
rical or symmetrical dimethylarginine revealed that CHTOP is
asymmetrically, but not symmetrically, dimethylated at arginine
residues in human embryonic kidney 293FT (HEK293FT) cells
(Figure 4B). Knockdown of PRMT1 using siRNA resulted in a
reduction in the asymmetrical methylation of arginine residues
in CHTOP. PRMT1 knockdown also led to a reduction in CHTOP,
especially the upper band of the doublet. In addition, as reported
previously (van Dijk et al., 2010), incubation of purified gluta-
thione S-transferase (GST)-PRMT1 and GST-CHTOP in vitro
resulted in the asymmetrical methylation of CHTOP (Figure 4C).
The asymmetrical methylation of CHTOP retarded its migration,
suggesting that the upper band of CHTOP detected in vivo may
represent the asymmetrically dimethylated form. We speculate
that arginine methylation of CHTOP may increase its molecular
weight and reduce its positive charge, causing its retarded
migration in SDS-PAGE.
We next examined the effect of arginine methylation on the
5hmC-binding activity of CHTOP. We found that knockdown
of PRMT1 suppressed the 5hmC-binding activity of CHTOP
(Figure 4D). By contrast, knockdown of PRMT5 barely
affected the arginine methylation or 5hmC-binding ability of0, October 9, 2014 ª2014 The Authors 51
(legend on next page)
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Figure 4. 5hmC Is Associated with CHTOP in Glioblastoma Cells
(A) CHTOP preferentially binds to 5hmC. Biotin-tagged oligonucleotides containing the indicated nucleotide modifications were incubated with lysates from
HEK293FT cells transfected with FLAG-CHTOP (upper panel) or recombinant CHTOP generated using the baculovirus system (lower panel). C, unmodified
cytosine; mC, 5-methylcytosine; hmC, 5-hydroxymethylcytosine.
(B) CHTOP is asymmetrically dimethylated by PRMT1, but not symmetrically by PRMT5. Lysates fromHEK293FT cells transfected with FLAG-CHTOP and siRNA
targeting PRMT1 or PRMT5 were subjected to immunoprecipitation with anti-FLAG antibody followed by immunoblotting with the indicated antibodies: asym24,
antibody against asymmetrically dimethylated arginine; sym10, antibody against symmetrically dimethylated arginine.
(C) PRMT1 asymmetrically dimethylates CHTOP in vitro. GST-CHTOPwas incubated with GST-PRMT1 in vitro and subjected to immunoblotting analysis with the
indicated antibodies. The upper band indicated by the arrowhead represents asymmetrically dimethylated CHTOP.
(D) PRMT1-mediated methylation of CHTOP is required for its binding to 5hmC. Lysates from HEK293FT cells transfected with FLAG-CHTOP and siRNA against
PRMT1 or PRMT5 were subjected to pull-down assays as in (A).
(E) CHTOP binds to 5hmC via its GAR motif. Lysates from HEK293FT cells transfected with FLAG-tagged wild-type or GAR mutant CHTOP were subjected to
pull-down assays as in (A). Sequences of the GAR motif of CHTOP are shown in the right panel. WT, wild-type.
See also Figure S3 and Table S2.CHTOP. Consistent with these results, a mutant CHTOP, in
which five arginine residues in the GAR region were replaced
with alanine, did not interact with 5hmC (Figure 4E). These
results suggest that PRMT1-mediated arginine methylation
is critical for the 5hmC-binding activity of CHTOP.
CHTOP Associated with 5hmC Recruits the
Methylosome
To further elucidate the function of CHTOP, we analyzed its
associated proteins in cell extracts. FLAG-CHTOP was over-
expressed in HEK293FT cells and immunoprecipitated with
anti-FLAG antibody followed by SDS-PAGE and silver stain-Figure 3. 5hmC Is Enriched in Genes Involved in Glioblastomagenesis
(A) Venn diagram showing the number of 5-hydroxymethylated genes in GB2 cel
specific for 5mC or 5hmC.
(B) Association of all peaks identified with various genomic features.
(C) 5hmC and 5mC are enriched in intragenic and upstream regions in GB2 cells
(D) 5mC and 5hmC profiles of the genes involved in glioblastomagenesis. Regi
indicate the peaks confirmed by hMeDIP-qPCR in (E).
(E) hMeDIP-qPCR assays were performed with glioblastoma cells and NPCs us
BCL2 and RXRA are positive controls for both glioblastoma cells and NPCs. Dat
(F) qRT-PCRanalysis of the indicated genes in GB2 cells andNPCs infectedwith a
type or mutant TET1. Data are the mean ± SD of three independent experiments
See also Table S1.ing. When coimmunoprecipitated proteins were analyzed by
LC-MS, we found that PRMT1, PRMT5, methylosome protein
50 (MEP50), and enhancer of rudimentary homolog (ERH)
were associated with CHTOP (Figure 5A; Table S3). Pull-
down assays using lysates from GB2 cells infected with a
lentivirus expressing wild-type or GAR mutant CHTOP
confirmed that CHTOP was associated with these proteins
(Figure 5B). Furthermore, we found that these proteins prefer-
entially bind to 5hmC-containing oligonucleotides (Figure 5C).
These proteins are components of an arginine methyltransfer-
ase complex, termed the methylosome (Friesen et al., 2001),
which is involved in several cellular processes, including thels and NPCs. (h)MeDIP-seq was performed with cell extracts using antibodies
.
ons in which signals were significantly enriched are marked in red. Asterisks
ing anti-5hmC antibody. SLC19A1 and ACSL3 are positive controls for NPCs.
a show the means ± SD of three independent experiments.
lentivirus expressing shRNA targeting TET1 and/or a lentivirus expressingwild-
. OE, overexpression.
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Figure 5. CHTOPAssociatedwith theMeth-
ylosome Binds to 5hmC
(A) CHTOP is associated with the methylosome.
Lysates from HEK293FT cells transfected with
FLAG-CHTOP were subjected to immunoprecipi-
tation with anti-FLAG antibody followed by SDS-
PAGE and silver staining, and coprecipitated
proteins were identified by mass spectrometry.
Asterisks indicate immunoglobulin chains.
(B) CHTOP is associated with the methylosome in
GB2 cells. The immunoprecipitates prepared as in
(A) were subjected to immunoblotting analysis
with the indicated antibodies.
(C) CHTOP and the methylosome preferentially
bind to 5hmC in GB2 cells.
(D) Immunoblotting analysis of methylosome
components extracted with salt buffer from the
chromatin fractions prepared from GB2 cells in-
fected with a lentivirus expressing the indicated
shRNAs and/or a lentivirus expressing wild-type
or mutant TET1 (upper panels) or CHTOP (lower
panels). KD, knockdown.
See also Figure S4 and Table S3.regulation of gene expression and RNA processing. Of partic-
ular note, it has been reported that PRMT1-mediated dime-
thylation of H4R3 is important for subsequent histone modifi-
cations such as acetylation and thereby is involved in
modulating transcriptional activation (Huang et al., 2005;
Wang et al., 2001).
To examine whether CHTOP is required for the association
of the methylosome with chromatin, chromatin samples pre-
pared from GB2 cells were incubated with NaCl and extracted
proteins were analyzed by immunoblotting analysis (Meshorer
et al., 2006). We found that knockdown of CHTOP resulted in
increased amounts of PRMT1, PRMT5, MEP50, and ERH
extracted from the chromatin fraction (Figures 5D, S4A, and
S4B). We also found that knockdown of TET1 led to the
increased extraction of these proteins, as well as increased
extraction of CHTOP. In addition, the increased extraction of
these proteins caused by knockdown of TET1 or CHTOP
could be suppressed by overexpression of wild-type TET1 or
CHTOP, but not of mutant TET1 or CHTOP. These results54 Cell Reports 9, 48–60, October 9, 2014 ª2014 The Authorssuggest that CHTOP associated with
5hmC functions as a recruiter of the
methylosome.
H4R3 Is Methylated by PRMTs in a
CHTOP- and/or TET1-Dependent
Manner
We next investigated whether H4R3 is
methylated by PRMTs in a CHTOP- and/
or TET1-dependent manner. Immuno-
blotting analysis revealed that knock-
down of either TET1 or CHTOP resulted
in a reduction in the amounts of both
H4R3me2a and H4R3me2s (Figure 6A).
We also performed chromatin immuno-
precipitation (ChIP) assays with anti-bodies against PRMT1, PRMT5, H4R3me2a, and H4R3me2s.
We found that these are associated with the EGFR, AKT3,
CDK6, CCND2, and BRAF genes, but not the HPRT1 gene (Fig-
ure 6B). Knockdown of either CHTOP or TET1 reduced the asso-
ciation of PRMT1 and PRMT5 with these genes (Figure 6B).
Furthermore, we found that knockdown of either CHTOP or
TET1 resulted in decreases in both the asymmetrical and sym-
metrical dimethylation of H4R3 (Figure 6B), whereas knockdown
of PRMT1 or PRMT5 led to a decrease in the asymmetrical or
symmetrical dimethylation of H4R3, respectively (Figure S5A).
We also found that knockdown of either TET1 or CHTOP led to
an increase in the trimethylation of H3K27, whereas the trimethy-
lation of H3K36 and the acetylation of H4 were not affected (Fig-
ure S5B). Consistent with these results, knockdown of either
CHTOP or PRMT1 suppressed the expression of these genes
(Figures 6C and 6D), whereas knockdown of PRMT5 barely
changed their expression, except for CCND2.
Consistent with the above findings, RNA sequencing
(RNA-seq) analyses revealed that knockdown of TET1,
Figure 6. The CHTOP-Methylosome Com-
plex Associated with 5hmC Methylates
H4R3 and Transactivates Cancer-Related
Genes
(A) Immunoblotting analysis of H4R3me2a and
H4R3me2s in GB2 cells infected with a lentivirus
expressing the indicated shRNAs and/or a lenti-
virus expressing wild-type or mutant TET1 (left
panels) or CHTOP (right panels).
(B) PRMTs and H4R3me2 are associated with
5hmC-enriched loci in a TET1- and CHTOP-
dependent manner. ChIP assays were performed
with GB2 cells transfected with the indicated
siRNAs. Data show the means ± SD of three
independent experiments.
(C) qRT-PCR analyses of the indicated genes were
performed using GB2 cells infected with a lenti-
virus expressing shRNA targeting CHTOP and/or a
lentivirus expressing wild-type or mutant CHTOP.
Data show the means ± SD of three independent
experiments.
(D) qRT-PCR analyses of the indicated genes were
performed using GB2 cells transfected with siRNA
targeting PRMT1 or PRMT5. Data show themeans
± SD of three independent experiments.
(E) RNA-seq analysis of GB2 cells transfected with
the indicated siRNAs.
(F) Scatterplot comparing transcriptome between
TET1 knockdown cells and CHTOP, PRMT1, or
PRMT5 knockdown cells. Genes whose expres-
sion was significantly changed are shown.
See also Figure S5.CHTOP, PRMT1, or PRMT5 resulted in similar changes in
gene-expression patterns in GB2 cells (Figures 6E and S5C)
and that the gene-expression profile of TET1 knockdown
cells strongly correlated with the profiles of cells in which
the other genes were knocked down (Figure 6F). In addition,
we found that 5hmC was overrepresented in the promoters
and intragenic regions of approximately 30% of genes whose
expression was significantly changed (false discovery rate
< 0.05).Cell Reports 9, 48–6CHTOP Is Required for Maintaining
5hmC Levels
We next examined the expression levels
of CHTOP in glioblastoma cells and
hNPCs. We found that GB2GB5,
GB11, and GB13 cells, but not GB1 cells,
express somewhat higher levels of
CHTOP than hNPCs (Figure S6A).
Furthermore, we found that knockdown
of CHTOP results in a reduction in global
5hmC levels in GB2 cells (Figure S6B).
We have also found that overexpression
of wild-type, but not of GAR mutant,
CHTOP restores 5hmC levels. These re-
sults suggest that CHTOP is required for
maintaining 5hmC levels and that upregu-
lation of CHTOP as well as TET1 is
responsible for the elevated levels of5hmC in glioblastoma cells. This may be one of the reasons
why 5hmC levels are not elevated in hNPCs, in which only
TET1, but not CHTOP, are upregulated.
CHTOP Is Required for the Tumorigenicity of
Glioblastoma Cells
Finally, we investigated the importance of CHTOP in the prolifer-
ation and tumorigenicity of glioblastoma cells. We found that
knockdown of CHTOP led to decreases in sphere formation of0, October 9, 2014 ª2014 The Authors 55
Figure 7. CHTOP Is Required for the Tumorigenicity of Glioblastoma Cells
(A) The number of spheres of glioblastoma cells transfected with siRNA targeting CHTOP. Data show the means ± SD of three independent experiments.
(B) The number of spheres of GB2 cells infected with a lentivirus expressing shRNA targeting CHTOP and/or a lentivirus expressing wild-type or mutant CHTOP.
Data show the means ± SD of three independent experiments.
(C) Growth curves of GB2 cells infected with a lentivirus expressing shRNA targeting CHTOP and/or a lentivirus expressing wild-type or mutant CHTOP.
Data show the means ± SD of three independent experiments.
(D) Kaplan-Meier survival curves of mice transplanted with 1.0 3 104 GB2 cells infected with a lentivirus expressing shRNA targeting CHTOP and/or a lentivirus
expressing wild-type or mutant CHTOP.
(E) Histological examination of tumors developed in the mice in (D). At day 100, tissue sections were stained with HE or anti-GFP antibody. The scale bars
represent 2 mm (upper panels) and 50 mm (lower panels).
(F) Schematic representation of 5hmC-mediated transcriptional activation. For details, see text.
See also Figure S6.GB2GB5 cells (Figures 7A and 7B) and GB2 cell proliferation
(Figure 7C). These phenotypes were rescued by overexpression
of wild-type CHTOP, but not by GAR mutant CHTOP. Mice
receiving shCHTOP-expressing GB2 cells survived significantly
longer than control mice (Figures 7D and 7E). Furthermore, we
found that overexpression of CHTOP restored the tumorigenicity
of shCHTOP-expressing GB2 cells (Figure 7D). These results
suggest that 5hmC serves as a recruitment signal for the56 Cell Reports 9, 48–60, October 9, 2014 ª2014 The AuthorsCHTOP-methylosome complex, which in turn methylates H4R3
and thereby activates the transcription of genes required for glio-
blastomagenesis (Figure 7F).
DISCUSSION
It is well known that glioblastomas contain genetic alterations in
the p53, RB, and RTK pathways (Chen et al., 2012; Parsons
et al., 2008; Cancer Genome Atlas Research Network, 2008), as
well as other genes, including the neurofibromatosis type 1 gene
(Cancer Genome Atlas Research Network, 2008), the NF-kB in-
hibitor a gene (Bredel et al., 2011), and/or the IDH1 gene (Par-
sons et al., 2008). In the present study, we have shown that
epigenetic alterations are also critical for the tumorigenicity of
glioblastoma cells. We showed that proneural glioblastoma con-
tains elevated levels of 5hmC and TET1 and that TET1-mediated
production of 5hmC is required for glioblastomagenesis. We
found that knockdown of TET1 in glioblastoma cells resulted in
decreases in their proliferation, sphere formation, and tumorige-
nicity. Furthermore, we demonstrated that ectopic overexpres-
sion of wild-type, but not of a catalytically inactive mutant,
TET1 restored the growth, sphere formation, and tumorigenicity,
as well as 5hmC levels in glioblastoma cells in which TET1 had
been knocked down.
Our results are in striking contrast to previous studies showing
that 5hmC levels are markedly reduced in many tumor cells
(Haffner et al., 2011; Kraus et al., 2012; Mu¨ller et al., 2012; Orr
et al., 2012). This may be due to the differences in the culture
conditions used and/or tumor subtypes. We cultured primary
glioblastoma cells in serum-free conditions to retain their stem-
cell-like properties and tumorigenicity. Indeed, our results
showed that HeLa and U87MG cells cultured in the presence
of serum contain extremely low levels of 5hmC.
Although most of previous studies did not consider subtypes
of glioblastoma, Noushmehr et al. (2010) have reported that
the IDH1 mutation is highly enriched in recurrent and secondary
proneural glioblastoma and is strongly linked to the glioma-CpG
island methylator phenotype (G-CIMP). Thus, secondary pro-
neural glioblastomas are expected to have lower 5hmC levels.
However, they have also reported that only a minor population
of primary glioblastoma patients (<10%) display G-CIMP and
IDH1 mutations. In this study, we focused on primary glioblas-
tomas that can be cultured in serum-free media and found that
most of the glioblastoma cell lines we established belong to
the proneural subtype. Furthermore, we performed dot blot anal-
ysis of 5hmC using glioblastoma specimens of all subtypes and
found that primary proneural glioblastomas that do not have an
IDH1 mutation have markedly higher levels of 5hmC compared
to other subtypes. We speculate that 5hmC may function differ-
ently at the molecular level in primary proneural glioblastoma
compared to other subtypes of glioblastoma and other tumor
cell types, and accordingly, 5hmC may recruit different mole-
cules and elicit different downstream signals in proneural glio-
blastoma cells than it does in other tumor cells.
We have shown that 5hmC is not simply a demethylation inter-
mediate but rather functions itself as an epigenetic mark modu-
lating gene expression. Our results are consistent with previous
findings showing that 5hmC is stably present in the genomes of
ESCs and neuronal cells (Ficz et al., 2011; Guo et al., 2011; Hahn
et al., 2013; Wu et al., 2011) and that enrichment of 5hmC is not
necessarily associated with DNA demethylation (Hahn et al.,
2013). Furthermore, Mbd3/NURD and MeCP2 have been re-
ported to bind to both 5hmC and 5mC (Melle´n et al., 2012; Yil-
dirim et al., 2011). A systematic analysis of 5hmC-binding pro-
teins using quantitative mass-spectrometry-based proteomics
has identified a number of specific 5hmC-binding proteins(Spruijt et al., 2013). These reported results suggested that
5hmC, 5fC, and 5caC may recruit transcription regulators in
certain cell types, as well as DNA repair proteins, which may
also be involved in DNA demethylation. CHTOP was not identi-
fied in this latter study, presumably because this laboratory
used mouse ESCs, mNPCs, and adult mouse brain tissue.
We found that TET1-mediated enrichment of 5hmC is critical
for the expression of a number of cancer-related genes such
as EGFR, AKT3, CDK6, CCND2, and BRAF. Furthermore, we
found that CHTOP associated with 5hmC recruits the methylo-
some and that a component of the methylosome complex,
PRMT1, methylates H4R3 and transactivates these genes. We
investigated these genes because their products are key com-
ponents of the RTK/RAS/PI(3)K- or the RB-signaling pathways
and have been reported to be frequently altered in glioblastoma
and play critical roles in glioblastomagenesis (Chen et al., 2012;
Parsons et al., 2008; Cancer Genome Atlas Research Network,
2008). We would like to investigate whether hydroxymethylation
of these five genes is necessary for the tumorigenicity of glio-
blastoma cells in future studies.
We found that TET1 knockdown in GB2 cells alters expression
of many genes that do not have 5hmC peaks. It is possible that
alterations in the expression of the genes that have 5hmC may
affect that of other genes that do not have 5hmC. In addition,
previous studies have shown that the TET family of proteins
can interact with O-linked N-acetylglucosamine transferase
(OGT) and function as a recruiter of OGT to chromatin (Chen
et al., 2013; Deplus et al., 2013; Vella et al., 2013). We therefore
speculate that TET1 has an important role that is independent of
its catalytic activity.
Interestingly, we found that knockdown of CHTOP results in a
reduction in global 5hmC levels in glioblastoma cells, whereas
overexpression of CHTOP restores 5hmC levels. Thus, CHTOP
may be required for maintaining 5hmC levels. For example,
CHTOP may protect 5hmC from demethylation. Our results sug-
gest that upregulation of CHTOP aswell as TET1may be respon-
sible for the elevated levels of 5hmC observed in glioblastoma
cells. We would like to investigate this issue in more detail in
future studies. In addition, we found that hNPCs express some-
what lower levels of CHTOP than glioblastoma cells. It is there-
fore possible that reduced expression of CHTOP in hNPCs con-
tributes, at least in part, to the poor expression of 5hmC, despite
high TET1 expression in these cells.
Glioblastoma stem cells are subsets of glioblastoma cells that
possess the capability of self-renewal and exhibit extensive
tumorigenicity (Gilbertson and Rich, 2007; Lathia et al., 2011;
Singh et al., 2004). Glioblastoma stem cells have been reported
to be resistant to both chemotherapy and radiotherapy and
thus are responsible for the poor prognosis of glioblastoma
(Bao et al., 2006; Chen et al., 2012). In this study, we utilized
glioblastoma cells cultured in serum-free medium, which
enriches for glioblastoma stem cells (Lee et al., 2006). Thus, it is
possible that 5hmC is critical for the tumorigenicity of
glioblastoma stem cells. To test this possibility, we need to
analyze the CD15- and/or CD133-positive stem cell population
(Singhetal., 2004;Sonetal., 2009). It also remains tobeexamined
whether 5hmC is required specifically for glioblastoma stem cells
or required for both glioblastoma stem and nonstem cells.Cell Reports 9, 48–60, October 9, 2014 ª2014 The Authors 57
In conclusion, we found that 5hmC recruits the CHTOP-meth-
ylosome complex, which methylates H4R3 and transactivates
cancer-related genes. Of particular interest is the fact that
knockdown of TET1 as well as CHTOP results in the strong
suppression of glioblastoma cell tumorigenicity. We therefore
speculate that TET1 could be a promising molecular target for
glioblastoma therapy. Because TET1-deficient mice are viable
and fertile (Dawlaty et al., 2011, 2013), compounds targeting
TET1 would be expected to have few serious side effects.
EXPERIMENTAL PROCEDURES
Antibodies
Antibodies used in immunoblot, ChIP, and (h)MeDIP assays are listed in
Table S4.
Cell Culture
Following informed consent, tumor samples classified as primary glioblastoma
were obtained from patients undergoing surgical treatment at the University
of Tokyo Hospital, as approved by the Institutional Review Board. Mouse
experiments were also approved by the Institutional Review Board. Tumors
were washed and mechanically and enzymatically dissociated into single
cells. Tumor cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 (Life Technologies) containing B27 supplement minus vitamin
A (Life Technologies), epidermal growth factor, and fibroblast growth factor
2 (20 ng/ml each; Wako Pure Chemicals Industries). Fetal and ESC-derived
hNPCs were purchased from Lonza and Millipore, respectively, and cultured
under the same conditions. HEK293FT, HeLa, and human glioblastoma
U87MG cells were cultured in DMEM (Nissui) containing 10% fetal bovine
serum. GB2 cells transfected with siRNA targeting TET1 or control were
seeded into a 96-well plate at the indicated cell number. The number of
spheres was counted after 7 days. Cell viability was measured by CellTiter-
Glo (Promega) according to the manufacturer’s instructions.
RNAi
For lentivirus production, the lentiviral vector CS-Rfa-CG harboring an shRNA
driven by the H1 promoter was transfected with the packaging vectors pCAG-
HIV-gp and pCMV-VSV-G-RSV-Rev into HEK293FT cells using Lipofectamine
2000 Transfection Reagent (Life Technologies). All plasmids were kindly
provided by H. Miyoshi (RIKEN BioResource Center). Virus supernatants
were purified by ultracentrifugation at 25,000 rpm at 4C for 90 min (SW28
rotor; Beckman Coulter Genomics). The target sequences for shRNAs are
as follows: shTET1 no.1: 50-GCATATTCCTTTGAAATAA-30; shTET1 no. 2: 50-
GAACTAAACAAGATTAAGT-30; shCHTOP no. 1: 50-CTAAATGAGCGCTTTA
CTA-30; shCHTOP no. 2: 50-CCAAGATGTCTCTAAATGA-30. The infection
efficiency of the lentiviruses was more than 95%, as judged by GFP or Venus
fluorescence. Transfection of Stealth siRNA duplexes targeting human TET1
(Life Technologies; catalog no. 10620318 and 10620319) or Silencer Select
Pre-Designed siRNA targeting human CHTOP (Life Technologies; catalog
no. s25092 and s25093) were performed using Lipofectamine RNAiMAX
(Life Technologies) according to the manufacturer’s instructions.
RNA Isolation and qRT-PCR
Total RNA was prepared by the NucleoSpin RNA Clean-up kit (Macherey-
Nagel) and reverse transcribed with PrimeScript Reverse Transcriptase
(TaKaRa). qPCR reactions were performed with Sybr Green I using a
LightCycler480 (Roche Applied Science). The results were normalized with
the detected values for TATA box-binding protein mRNA. Absolute mRNA
levels of the TET family of genes were determined according to the standard
curves generated by serial dilutions of plasmids containing TET1TET3.
Primers used in qRT-PCR are shown in Table S5.
(h)MeDIP
Cells were digested with proteinase K and RNase A, and genomic DNA
was purified by phenol/chloroform extraction. Purified genomic DNA was58 Cell Reports 9, 48–60, October 9, 2014 ª2014 The Authorssonicated to 200–500 bp with a Handy Sonic (TOMY). (h)MeDIP was per-
formed as described previously (Weber et al., 2005) with minor modifications.
Briefly, 4 mg of fragmented genomic DNA was immunoprecipitated with 4 ml of
polyclonal antibody against 5hmC (Active Motif) or 4 mg of monoclonal anti-
body against 5mC (Eurogentec) at 4C overnight in a 500 ml of IP buffer
(10 mM sodium phosphate [pH 7.0], 140 mM NaCl, and 0.05% Triton
X-100). The mixture was incubated with 30 ml of Dynabeads Protein G at 4C
for 2 hr and washed three times with 1 ml of IP buffer. The beads were
suspended in 20 mg of proteinase K and incubated at 55C for at least 3 hr.
Immunoprecipitated DNA was purified by phenol/chloroform extraction
followed by isopropanol precipitation.
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